2[1]THRMANN PA. Angiotensin II antagonism and the heart: valsartan in left ven tricular hypertrophy [J]. J Cardiovasc Pharmacol ,1999, 33 Suppl 1:S33-S36.
3[2]PLUM J, BNTEN B, N**METH R, et al. Effects of the angiotensin II ant agonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients wit h chronic renal failure and hypertension [J]. J Am Soc Nephrol, 1998, 9(12): 2 223-2234.
4[3]BREMNER AD, BAUR M, ODDOU-STOCK P, et al. Valsartan: long term effica cy and tolerability compared to lisinopril in elderly patients with essential hypertens ion [J]. Clin Exp Hypertens, 1997, 19(8): 1263-1285.
5[4]MARKHAM A, GOA KL. Valsartan a review of its pharmacology and therapeutic use in essential hypertension [J]. Drugs ,1997 ,54(2): 299-311.
6[5]BLACK HR, GRAFF A, SHUTE D, et al. Valsartan, a new angiotensin II ant agonis t for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril [J]. J Hu m Hypertens, 1997,11(8): 483-489.
7[10]NAKASHIMA M, UMEMURA K. The clinical pharmacology of losartan in Japanese subjects and patients[J]. Blood Press Suppl,1996,2:62-66.
8[11]SONG JC, WHITE CM. Pharmacologic, pharmacokinetic, and therapeutics differences among angiotensin Ⅱreceptor antagonists [J]. Pharmacotherapy, 2000,20(2):130-139.
9[12]NEUTEL JM, KLEIN C, MEINICKE TW, et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications[J].Blood Press,2002,11(5):302-309.
10[13]PRASAD PP, YEH CM, GURRIERI P, et al. Pharmacokinetics of multiple doses of valsartan in patients with heart failure[J]. J Cardiovasc Pharmacol,2002,40(5):801-807.